From GlobeNewswire: 2025-02-12 16:05:00

Ascendis Pharma A/S plans to use $25 million in the first quarter of 2025 to fund a share repurchase program and net settle certain RSUs. The program aims to repurchase up to $18.25 million of the company’s ADSs, preserving approximately 200,000 ADSs as treasury shares. Purchases may be made through various methods, including open market purchases and block trades. Ascendis Pharma is focused on using its TransCon technology platform to develop innovative therapies and make a difference in patients’ lives. The company urges caution regarding forward-looking statements due to potential risks and uncertainties.



Read more at GlobeNewswire: Ascendis Pharma A/S Announces Share Repurchase Program &